BioTime gets $4.7M stem cell agency grant
BioTime Inc. said Thursday it got a $4.7 million grant from California’s stem cell agency to study using BioTime technology to create patient-specific medicines. Alameda-based BioTime (OTCBB: BTIM) has technology it calls ACTCellerate based on …
[Read the full article here]Related News:
BioTime wins $4.7m grant from CIRM
BioTime Adds Five New Stem Cell Lines to Its Product …
BioTime Adds Five New Stem Cell Lines to Its Product Portfolio